Tech Tour AI for Health 2026 Top Presenters
The Tech Tour AI for Health 2026 Investment Programme concluded with an event on 11–13 March 2026 in Bochum, Germany. More than 30 selected companies presented their innovations to a room of leading investors and healthcare experts. Across the programme’s core tech tracks, Drug Discovery, Prevention and Virtual Care, entrepreneurs demonstrated how artificial intelligence is transforming diagnostics, treatment and patient care.
Seven companies were recognized by the Expert Jury for their outstanding presentations.
Top Presenting Companies
Ebenbuild develops AI-powered digital twins of the lungs, combining physics-based simulation and patient data to improve treatment decisions in respiratory diseases, enable in-silico trials for drug development and support clinicians in optimising mechanical ventilation strategies.
expressTEC develops AI-enabled RNA-based companion diagnostics that improve how cancer patients are matched to targeted therapies. Its platform combines proprietary RNA assays and decision-support software to identify tumours compatible with specific pathway inhibition treatments.
ImageBiopsy Lab transforms routine X-rays into actionable surgical intelligence using AI-powered musculoskeletal imaging analysis. Its platform helps clinicians improve diagnostic precision, optimise surgical decisions and detect conditions such as osteoporosis earlier.
Innocens develops AI-driven clinical decision support systems for intensive care. Its Intellicens Data and AI Platform predicts neonatal sepsis risk using real-time patient data, enabling earlier interventions, improved outcomes and shorter ICU stays.
INTA develops portable diagnostic devices for detecting traumatic brain injuries through blood analysis. Its flagship product, NanoAnalyzer, is an AI-powered multiplex biosensor system that detects multiple biological analytes simultaneously, enabling rapid and cost-effective diagnostics.
SOENIA® by BrainCare Oy develops remote neurological monitoring solutions for patients with neurological disorders. Its technology includes a subscalp EEG for long-term seizure monitoring in refractory epilepsy and ongoing neuromodulation research.
Synagen develops an oncology-focused agentic AI co-pilot that supports cancer care teams with tumour board preparation, treatment planning and clinical trial matching. The platform transforms hospital data into structured patient insights to help deliver faster, more consistent and personalised care.
Don’t miss out on our upcoming events and the latest industry innovations — explore the next Tech Tour programmes.
Newsletter
Stay up to date with market insights, trailblazing investment cases, and leadership profiles by subscribing to our newsletter.